Dr Reddy's Laboratories Ltd (RDY) Stock Analysis
Verdict: AVOID
Massive Q1 earnings miss and Semaglutide setbacks invalidate the growth thesis, leaving the stock in a high-risk technical breakdown.
Investment score: 38/100
Analysis as of
Is Dr Reddy's Laboratories Ltd stock worth reviewing? The TradeMates thesis
The TradeMates model sees a fundamental breakdown following a 70% YoY earnings decrease and strategic delays in the high-growth GLP-1 (Semaglutide) segment.
7-factor investment score
- Valuation: 48/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 45/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Dr Reddy's Laboratories Ltd opportunities and risks
What speaks for RDY
- Domestic Market Strength
What speaks against RDY
- U.S. Market Barriers & Tariffs
Peers and competitors
- TORNTPHARM.NS
- CIPLA.NS
- LUPIN.NS
- ZYDUSLIFE.NS
- MANKIND.NS
Frequently asked questions about Dr Reddy's Laboratories Ltd (RDY)
Is RDY stock a good investment?
The TradeMates model rates Dr Reddy's Laboratories Ltd as AVOID with an investment score of 38/100. The TradeMates model sees a fundamental breakdown following a 70% YoY earnings decrease and strategic delays in the high-growth GLP-1 (Semaglutide) segment. This is algorithmic model output, not personal investment advice.
Is RDY stock a buy?
The TradeMates model verdict for RDY is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.